The compound 1-methyl-d,l-tryptophan (1MT) is an inhibitor of IDO1, and single-agent administration of 1MT has delayed tumor outgrowth in a transgenic model of human epidermal growth factor receptor 2 (HER2)-driven breast cancer [21]. The gene discussed is ERBB2; the disease is breast cancer.